NEW YORK (GenomeWeb) – Newly minted computational genomics firm Phosphorus is hoping to build its business around bioinformatics solutions that support genetic testing laboratories as well as clinical tests for identifying patients' predispositions to cardiovascular disease and other conditions.

The company is preparing to launch two new genetic tests in 2017 and helping a number of unnamed clinical labs implement its lab management and variant analysis and reporting software, Phosphorus Founder and CEO Alexander Bisignano told GenomeWeb this week.

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.